Evaluating the Scientific Evidence for Potential Reduced-Risk Tobacco Products   Biological Effects Assessment (BEA) Committee   Meeting #2: September 27-28, 2005 PRELIMINARY AGENDA   Day One: September 27 (8 a.m. - 6 p.m.)     Executive Session (8 a.m. - 6 p.m.)   I.  Opening Remarks and Review of Agenda   II.  Overview of Chronic Obstructive Pulmonary Disease (COPD) Biomarkers     LUNCH   III.  Overview of Cardiovascular Disease (CVD) Biomarkers   IV.  Overview of Lung Cancer Biomarkers   V.  Wrap-up of COPD, CVD, and Lung Cancer Biomarkers Close (6 p.m.)     Day Two: September 28 (8 a.m. - 3 p.m.)     Executive Session (8 a.m. - 3 p.m.)   I.  Discussion of a Potential Biomarker Strategy for Testing Reduced Risk Products   II.  Discussion of the Limits of Potential Biomarkers and Critical Aspects of Future Biomarker Development     LUNCH   III.  Discussion of Biomarker Definitions   IV.  Discussion of Committee needs for literature, presentations, etc. Discussion of BEA meeting schedule Adjourn (3 p.m.)